These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 28395551)

  • 1. Use of tigecycline in pediatric clinical practice.
    Mastrolia MV; Galli L; De Martino M; Chiappini E
    Expert Rev Anti Infect Ther; 2017 Jun; 15(6):605-612. PubMed ID: 28395551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections.
    Ku K; Pogue JM; Moshos J; Bheemreddy S; Wang Y; Bhargava A; Campbell M; Khandker N; Lephart PR; Chopra T; Hayakawa K; Martin ET; Abreu-Lanfranco O; Dhar S; Kaye KS; Marchaim D
    Am J Infect Control; 2012 Dec; 40(10):983-7. PubMed ID: 22440526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minocycline--an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii.
    Bishburg E; Bishburg K
    Int J Antimicrob Agents; 2009 Nov; 34(5):395-401. PubMed ID: 19665876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of tigecycline against extended-spectrum β-lactamase-producing Enterobacteriaceae and MRSA clinical isolates from Mexico: a multicentric study.
    Silva-Sanchez J; Reyna-Flores F; Velazquez-Meza ME; Rojas-Moreno T; Benitez-Diaz A; Sanchez-Perez A;
    Diagn Microbiol Infect Dis; 2011 Jun; 70(2):270-3. PubMed ID: 21596226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical experience with tigecycline in the treatment of nosocomial infections caused by isolates exhibiting prevalent resistance mechanisms].
    Giménez MJ; García-Rey C; Barberán J; Aguilar L
    Rev Esp Quimioter; 2009 Mar; 22(1):48-56. PubMed ID: 19308747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009.
    Morfin-Otero R; Dowzicky MJ
    Clin Ther; 2012 Jan; 34(1):101-12. PubMed ID: 22177546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome.
    Kim NH; Hwang JH; Song KH; Choe PG; Kim ES; Park SW; Kim HB; Kim NJ; Park WB; Oh MD
    Scand J Infect Dis; 2013 Apr; 45(4):315-9. PubMed ID: 23113680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
    Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
    J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure.
    Liou BH; Lee YT; Kuo SC; Liu PY; Fung CP
    Antimicrob Agents Chemother; 2015; 59(6):3637-40. PubMed ID: 25824230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline.
    Gordon NC; Wareham DW
    J Antimicrob Chemother; 2009 Apr; 63(4):775-80. PubMed ID: 19158109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
    Koomanachai P; Kim A; Nicolau DP
    J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug-resistant Acinetobacter baumannii bacteremia treated with tigecycline in two pediatric burn patients.
    Kanık-Yüksek S; Tezer H; Ozkaya-Parlakay A; Gulhan B; Sayed-Oskovi H; Kara A; Şenel E
    Pediatr Infect Dis J; 2015 Jun; 34(6):677. PubMed ID: 25970113
    [No Abstract]   [Full Text] [Related]  

  • 14. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
    Pfaller MA; Mendes RE; Castanheira M; Flamm RK; Jones RN; Sader HS
    Pediatr Infect Dis J; 2017 May; 36(5):486-491. PubMed ID: 28403050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective analysis of tigecycline shows that it may be an option for children with severe infections.
    Zhu ZY; Yang JF; Ni YH; Ye WF; Wang J; Wu ML
    Acta Paediatr; 2016 Oct; 105(10):e480-4. PubMed ID: 27381360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience of tigecycline treatment in infections caused by extensively drug-resistant Acinetobacter spp.
    Moon SY; Peck KR; Chang HH; Kim SW; Heo ST; Son JS; Ryu SY; Moon C; Jung SI; Shin SY; Lee JA; Joung MK; Chung DR; Kang CI; Song JH
    Microb Drug Resist; 2012 Dec; 18(6):562-6. PubMed ID: 22775562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii.
    Schafer JJ; Goff DA; Stevenson KB; Mangino JE
    Pharmacotherapy; 2007 Jul; 27(7):980-7. PubMed ID: 17594203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections.
    Metan G; Alp E; Yildiz O; Percin D; Aygen B; Sumerkan B
    J Chemother; 2010 Apr; 22(2):110-4. PubMed ID: 20435570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of tigecycline against Acinetobacter baumannii isolates from a teaching hospital in Malaysia.
    Dhabaan GN; AbuBakar S; Shorman MA; Hassan H
    J Chemother; 2012 Apr; 24(2):87-92. PubMed ID: 22546763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation.
    Nix DE; Matthias KR
    J Antimicrob Chemother; 2010 Jun; 65(6):1311-2. PubMed ID: 20378673
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.